Researcher
Sylvie Rottey
- Disciplines:Cancer therapy, Oncology not elsewhere classified, Cancer biology
Affiliations
- Department of Basic and Applied Medical Sciences (Department)
Member
From1 Oct 2018 → Today - Department of Pharmacology (Department)
Member
From1 Oct 2008 → 30 Sep 2018
Projects
1 - 2 of 2
- Universal, cost-effective and hypersensitive open-source technology platform for liquid biopsy based on methylome profiling of circulating DNA.From1 Jan 2024 → TodayFunding: BOF - projects
- Prediction of immunotherapy response and toxicity in melanoma, renal cell and lung cancer using transcriptome based systemic immune phenotyping.From1 Nov 2021 → TodayFunding: FWO fellowships
Publications
1 - 10 of 103
- A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection(2023)
Authors: RP Matthews, X Zang, SE Barrett, A Koynov, A Goodey, T Heimbach, VL Weissler, C Leyssens, T Reynders, Z Xu, et al.
Pages: 310 - 316 - Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers(2023)Volume: 142
Authors: Sylvie Rottey, Nikhil Singh, Emily Labriola-Tompkins, Heinrich E Lob, Kusha Mohammadi, Hazem Hassan, Lorna Farrelly, Swati Duggal, Harvey Chin, Sarah Hatsell, et al.
Pages: 3841 - 3841 - Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer(2023)
Authors: Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, et al.
Pages: 301 - 315 - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3(2023)Volume: 34
Authors: J. Mazieres, M. Duruisseaux, H. Curcio, C. Morizane, R. Galot, Sylvie Rottey, J. A. Stratmann, Y. Ma, M. Bouzaggou, L. Geng, et al.
Pages: S1076 - S1077 - Infrared spectroscopy : a new frontier in hematological disease diagnosis(2023)
Authors: Charlotte Delrue, Reinhart Speeckaert, Matthijs Oyaert, Tessa Kerre, Sylvie Rottey, Renaat Coopman, Wouter Huvenne, Sander De Bruyne, Marijn Speeckaert
- Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants(2023)
Authors: Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, et al.
Pages: 1947 - 1956 - Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial(2023)
Authors: Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, et al.
Pages: 1205 - 1213 - GeNeo : agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative(2023)Volume: 34
Authors: P. G. Aftimos, K. Punie, L. Decoster, C. Van Marcke de Lummen, A. Hebrant, G. Raicevic, E. Van Valckenborgh, B. Maes, J. Maetens, J. J. Collignon, et al.
Pages: S253 - S254 - Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose : a retrospective cohort study(2023)
Authors: Koen Kortbeek, Sigurd Delanghe, Sylvie Rottey, Hannelore Denys, Lore Lapeire
Pages: 298 - 307 - Safety and tolerability of topical polyhexamethylene biguanide : a randomised clinical trial in healthy adult volunteers(2022)
Authors: Vincenzo Papa, Ivanka van der Meulen, Sylvie Rottey, Guy Sallet, Jolanda Overweel, Nino Asero, Darwin C Minassian, John K G Dart
Pages: 190 - 196